![Peter Pack](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Peter Pack
Nessuna posizione attualmente
Storia della carriera di Peter Pack
Precedenti posizioni note di Peter Pack
Società | Posizione | Inizio | Fine |
---|---|---|---|
OXFORD BIODYNAMICS PLC | Direttore/Membro del Consiglio | 05/04/2019 | 04/06/2020 |
Presidente | 04/06/2020 | 14/12/2020 | |
Independent Dir/Board Member | 05/04/2019 | 14/12/2020 | |
Crescendo Biologics Ltd.
![]() Crescendo Biologics Ltd. Miscellaneous Commercial ServicesCommercial Services Crescendo Biologics Ltd. engages in the development of new medicines based on antibody fragment technology. Its products in pipeline in dermatology include CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The firm?s oncology products in pipeline include Humabody Multi-Specific T-Cell Engagers, Humabody Antibody Drug Conjugates and Immune Checkpoint Inhibitors. The company was founded by Michael Anthony Romanos, David Rayll Brown and John Bradshaw on November 13, 2007 and is headquartered in Cambridge, the United Kingdom. | Direttore/Membro del Consiglio | 01/08/2015 | 01/05/2019 |
Amministratore Delegato | 01/08/2015 | 01/05/2019 | |
mtm laboratories AG
![]() mtm laboratories AG Medical SpecialtiesHealth Technology mtm laboratories AG is an ISO 9001 and 13485 certified developer and manufacturer of In-Vitro Diagnostics for the early detection and diagnosis of cervical and other cancers. With headquarters in Heidelberg, Germany, and subsidiaries in the United States, France, Italy and Spain, mtm markets its proprietary CINtec® Histology kit and CINtec® Cytology kit as adjunct tools for the early detection and diagnosis of cervical cancer. These kits are based on mtm's proprietary E6H4™ antibody clone which was specifically developed for immunochemistry applications in both formalin-fixed paraffin-embedded tissue sections and alcohol fixed cervical cytology preparations. The target for mtm's cervical cancer early detection technology platforms is the evaluation of the over-expression of the cyclin-dependent kinase inhibitor p16INK4a. This sensitive and selective antibody clone is combined with GMP manufactured kit components to ensure reproducible quality and results. mtm laboratories AG also has programs to identify and develop biomarker based diagnostics for other cancer indications. With its extensive and ever increasing network of clinical research institutions, academic research organizations, and medical professionals active in the field of oncology and molecular pathology, mtm has established a rapid, integrated process for the successful identification and clinical validation of molecular markers associated with cancer. | Fondatore | 14/11/2008 | 14/11/2008 |
Presidente | - | 14/11/2008 | |
Polyplus-transfection SA
![]() Polyplus-transfection SA BiotechnologyHealth Technology Polyplus-transfection SA develops and sells solutions for the delivery of nucleic acids in research, bio production, and therapeutics. Its products are transfection reagents and trademarks, mainly for gene and cell therapies. The company was founded by Jean-Paul Behr, Anne-Lise Monjanel, Joelle Bloch, and Patrick Metz in January 2001 and is headquartered in Illkirch-Graffenstaden, France. | Direttore/Membro del Consiglio | - | - |
MORPHOSYS AG | Direttore Tecnico/Scientifico/R&S | - | - |
Polytech Domilens GmbH
![]() Polytech Domilens GmbH Electronic ComponentsElectronic Technology Polytech Domilens GmbH provides products and services in the field of ophthalmic surgery. It specializes in the areas of cataract surgery, iris-prosthetics, refractive and trauma surgery, and glaucoma. The company was founded in 1989 and is headquartered in Rossdorf, Germany. | Corporate Officer/Principal | - | - |
Formazione di Peter Pack
University of Münster | Undergraduate Degree |
Ludwig-Maximilians-Universität München | Doctorate Degree |
Statistiche
Distribuzione geografica
Germania | 6 |
Regno Unito | 3 |
Francia | 2 |
Posizioni
Director/Board Member | 3 |
Undergraduate Degree | 1 |
Doctorate Degree | 1 |
Settori
Health Technology | 5 |
Consumer Services | 3 |
Electronic Technology | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 2 |
---|---|
MORPHOSYS AG | Health Technology |
OXFORD BIODYNAMICS PLC | Health Technology |
Aziende private | 4 |
---|---|
Polytech Domilens GmbH
![]() Polytech Domilens GmbH Electronic ComponentsElectronic Technology Polytech Domilens GmbH provides products and services in the field of ophthalmic surgery. It specializes in the areas of cataract surgery, iris-prosthetics, refractive and trauma surgery, and glaucoma. The company was founded in 1989 and is headquartered in Rossdorf, Germany. | Electronic Technology |
mtm laboratories AG
![]() mtm laboratories AG Medical SpecialtiesHealth Technology mtm laboratories AG is an ISO 9001 and 13485 certified developer and manufacturer of In-Vitro Diagnostics for the early detection and diagnosis of cervical and other cancers. With headquarters in Heidelberg, Germany, and subsidiaries in the United States, France, Italy and Spain, mtm markets its proprietary CINtec® Histology kit and CINtec® Cytology kit as adjunct tools for the early detection and diagnosis of cervical cancer. These kits are based on mtm's proprietary E6H4™ antibody clone which was specifically developed for immunochemistry applications in both formalin-fixed paraffin-embedded tissue sections and alcohol fixed cervical cytology preparations. The target for mtm's cervical cancer early detection technology platforms is the evaluation of the over-expression of the cyclin-dependent kinase inhibitor p16INK4a. This sensitive and selective antibody clone is combined with GMP manufactured kit components to ensure reproducible quality and results. mtm laboratories AG also has programs to identify and develop biomarker based diagnostics for other cancer indications. With its extensive and ever increasing network of clinical research institutions, academic research organizations, and medical professionals active in the field of oncology and molecular pathology, mtm has established a rapid, integrated process for the successful identification and clinical validation of molecular markers associated with cancer. | Health Technology |
Crescendo Biologics Ltd.
![]() Crescendo Biologics Ltd. Miscellaneous Commercial ServicesCommercial Services Crescendo Biologics Ltd. engages in the development of new medicines based on antibody fragment technology. Its products in pipeline in dermatology include CB001, a transformational Humabody-based topical biologic for psoriasis which combines exceptional activity against a validated target with a topical route of delivery to avoid systemic side effects. The firm?s oncology products in pipeline include Humabody Multi-Specific T-Cell Engagers, Humabody Antibody Drug Conjugates and Immune Checkpoint Inhibitors. The company was founded by Michael Anthony Romanos, David Rayll Brown and John Bradshaw on November 13, 2007 and is headquartered in Cambridge, the United Kingdom. | Commercial Services |
Polyplus-transfection SA
![]() Polyplus-transfection SA BiotechnologyHealth Technology Polyplus-transfection SA develops and sells solutions for the delivery of nucleic acids in research, bio production, and therapeutics. Its products are transfection reagents and trademarks, mainly for gene and cell therapies. The company was founded by Jean-Paul Behr, Anne-Lise Monjanel, Joelle Bloch, and Patrick Metz in January 2001 and is headquartered in Illkirch-Graffenstaden, France. | Health Technology |
- Borsa valori
- Insiders
- Peter Pack
- Esperienza